Rocket


Overview
Financials
News + Filings
Key Docs
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

OPIANT PHARMACEUTICALS, INC. (LLTP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/13/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/06/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/06/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/06/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/06/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/02/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/02/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"SECOND AMENDED AND RESTATED BYLAWS OF OPIANT PHARMACEUTICALS, INC."
03/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/07/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC",
"Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC"
02/06/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/04/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
12/21/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
12/20/2022 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
12/07/2022 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
11/28/2022 SC 13G Western Standard LLC reports a 7.4% stake in Opiant Pharmaceuticals, Inc.
11/15/2022 8-K Quarterly results
11/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy